Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...4647484950515253545556...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma. (Pubmed Central) -  Oct 19, 2022   
    Erlotinib, an EGFR inhibitor that has also been shown to inhibit ABCB1, suppressed lenvatinib exocytosis, and combined treatment with lenvatinib and erlotinib demonstrated a significant synergistic effect on HCC both in vitro and in vivo. Taken together, these findings characterize a mechanism of resistance to a first-line treatment for HCC and offer a practical means to circumvent resistance and treat the disease.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker:  Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. (Pubmed Central) -  Oct 19, 2022   
    However, the field is currently still limited with the limited availability of biomarkers to inform on treatment selection and the lack of head-to-head studies across the effective RCC treatments. Ongoing and future studies are eagerly anticipated to uncover multiple unmet needs in RCC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jemperli (dostarlimab) / GSK, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Advanced and recurrent endometrial cancer: state of the art and future perspectives. (Pubmed Central) -  Oct 19, 2022   
    Phase II-III clinical trials in metastatic endometrial cancer are mainly focused on target therapies and immunotherapy as single agents or in combination. Unfortunately, most of these trials are lacking of predictive biomarkers of response to select patients most or at least likely to benefit from those treatments.
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  AK104-206: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 19, 2022   
    P1/2,  N=30, Recruiting, 
    Unfortunately, most of these trials are lacking of predictive biomarkers of response to select patients most or at least likely to benefit from those treatments. Unknown status --> Recruiting | Trial completion date: Mar 2022 --> Oct 2023 | Trial primary completion date: Jan 2022 --> Apr 2023
  • ||||||||||  Review, Journal:  Emerging Targets in Clear Cell Renal Cell Carcinoma. (Pubmed Central) -  Oct 15, 2022   
    The dual immune checkpoint blockade targeting CTLA-4 and PD-1 (ipilimumab/nivolumab) or the IO combinations targeting PD-1 and anti-VEGF TKIs (pembrolizumab/axitinib, nivolumab/cabozantinib, pembrolizumab/lenvatinib) have demonstrated an overall survival benefit in advanced clear cell renal cell carcinoma (ccRCC)...In addition, microbiome products enhancing IO response, antibody-drug conjugates, and targeted radionuclides are also being investigated. This review summarizes selected emerging agents that are under development in ccRCC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov) -  Oct 14, 2022   
    P2,  N=40, Not yet recruiting, 
    This review summarizes selected emerging agents that are under development in ccRCC. Trial completion date: Mar 2026 --> Dec 2026 | Initiation date: Apr 2022 --> Jan 2023 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) -  Oct 14, 2022   
    P1,  N=24, Completed, 
    Trial completion date: Mar 2026 --> Dec 2026 | Initiation date: Apr 2022 --> Jan 2023 | Trial primary completion date: Dec 2024 --> Dec 2025 Active, not recruiting --> Completed | Trial completion date: Apr 2023 --> Oct 2022 | Trial primary completion date: Apr 2023 --> Oct 2022
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Immune Checkpoint Inhibitor-Induced "Pantubulopathy" (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2890;    
    Case Description A 67 yo F w/ PMH of HTN, CKD3b (baseline SCr 1.3-1.6 from previous nephrotoxic exposure to carboplatin and bevacizumab), and metastatic endometrial cancer being treated with pembrolizumab (PD-1 inhibitor), lenvatinib (TK inhibitor), and zoledronic acid presented with a SCr of 3.2 mg/dl, hypokalemia (2.5 mmol/l), hypophosphatemia (1.9 mg/dl), hypomagnesemia (1.3 mg/dl), and a non-anion gap metabolic acidosis with [HCO 3 ] 14 mmol/l and arterial blood pH of 7.18...She received 40 mg prednisone with improvement in electrolyte disturbances and SCr to baseline...While each of these have been reported with CPI’s, we are unaware of a prior case of “pantubulopathy” in which every segment of the nephron was affected by the CPI-induced AIN. Prompt diagnosis and treatment led to complete resolution of AKI and tubular defects.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Role for Calcineurin Inhibitor in Tyrosine Kinase Inhibitor-induced Focal Segmental Glomerulosclerosis (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1074;    
    Discussion There are many documented cases of TKI-induced FSGS resistant to glucocorticoid treatment. Our case demonstrates that calcineurin inhibitors may have efficacy as a second-line treatment in these instances.
  • ||||||||||  Avastin (bevacizumab) / Roche
    A Rare Case of Membranoproliferative Glomerulonephritis (MPGN) With Bevacizumab (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1071;    
    She was previously treated with carboplatin, paclitaxel, docetaxel, bevacizumab and dexamethasone...She was started on prednisone 40mg, tapered in 3 months with improvement in Cr, proteinuria and remained stable despite switching to pembrolizumab and lenvatinib...But her kidney injury was temporally related to bevacizumab and followed discontinuation of dexamethasone suggesting potential development of antibodies to bevacizumab. Therefore, clinicians should be vigilant and practice low threshold for biopsy with patients on bevacizumab for appropriate management.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios. (Pubmed Central) -  Oct 13, 2022   
    In locally advanced or metastatic disease there are only two types of treatment available: radioactive iodine (RAI) while the disease is RAI-sensitive and multikinase inhibitors, lenvatinib and sorafenib, when the disease becomes RAI-refractory. The objective of this publication is to review the current knowledge on the use of targeted therapy and the specific practical considerations concerning lenvatinib in the treatment of patients with differentiated thyroid cancer under special circumstances.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, Combination therapy:  Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. (Pubmed Central) -  Oct 11, 2022   
    Patients should be followed also during treatment as some adverse events, e.g., cardiac dysfunction might appear later. Increased awareness on risk to benefit ratio among clinicians would be helpful to avoid dose interruptions or discontinuation of lenvatinib, with preferring other medical interventions and supportive care.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Adverse events:  Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib. (Pubmed Central) -  Oct 10, 2022   
    RNA seq analysis revealed enrichment of PI3K-AKT, MAPK, cAMP, Rap1 signaling pathways, ECM-receptor interaction, Focal adhesion, and steroid hormone biosynthesis pathways in the TAMR cells. Serum zonulin levels predict severe adverse events in patients with advanced hepatocellular carcinoma treated with lenvatinib.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population (Exhibition / Poster Area) -  Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_635;    
    Conclusions Our study did not identify any meaningful difference in overall survival between atezolizumab plus bevacizumab and lenvatinib. Although some hints are provided suggesting that patients with NASH/NAFLD might benefit more from lenvatinib therapy and patients with viral etiology more from atezolizumab plus bevacizumab.